Cartalax

Assumed mechanism (not proven in humans): as an ultrashort Khavinson 'peptide bioregulator,' AED is theorized to enter cells, reach the nucleus, and bind specific DNA/regulatory regions to modulate tissue-specific gene expression epigenetically rather than via classical receptor signaling. In cartilage this is proposed to upregulate matrix genes (type II collagen, aggrecan, proteoglycans) and downregulate matrix metalloproteinases, while shifting senescence markers (lower p16/p21/p53, higher SIRT6). Framed as assumed because the DNA-binding/gene-regulation model is largely cell-culture-derived and not validated as a clinical mechanism.

Adverse events

Most commonly reported (anecdotal / Russian literature) are injection-site reactions: mild redness, swelling, or tenderness. Scattered anecdotes mention transient fatigue or a brief 'flu-like' feeling after early doses and rare mild digestive upset. None of this is from a controlled human safety study.

Contraindications

No formal contraindication list exists because the compound was never through a regulated human program. Prudent caution: active or history of malignancy (given proliferative/epigenetic claims), pregnancy or breastfeeding, and known peptide/excipient allergy. There is no drug-interaction data.

Theoretical concerns

The proposed mechanism is epigenetic modulation of gene expression (chondrocyte matrix genes, senescence/longevity markers). Any agent claimed to alter gene-expression and cell-proliferation programs carries a theoretical concern about unintended proliferative or off-target tissue effects with chronic use, none of which has been characterized in humans. Sterility/contamination risk from reconstituting and injecting a non-pharmaceutical-grade research product is a real practical hazard.

What nobody knows yet

Essentially everything load-bearing is unknown in humans: efficacy, effective dose, true pharmacokinetics, long-term safety, oncologic safety of chronic epigenetic signaling, immunogenicity, and product identity/purity from gray-market suppliers. The absence of any registered trial means the risk-benefit ratio cannot honestly be estimated.

What else could explain the result

Users almost never run it alone. It is commonly stacked with other Khavinson bioregulators (notably Epitalon) and broader joint/recovery agents (BPC-157, TB-500, collagen, glucosamine, NSAIDs), plus training, weight, and load changes. Any perceived joint improvement is heavily confounded by these co-interventions, natural symptom fluctuation in osteoarthritis, and regression to the mean after a flare.

Is the vial what it says?

Cross-checked across a Wikipedia entry, the Khavinson/AED PubMed literature (which is mostly the related AEDG tetrapeptide, confirming how thin the AED-specific human/animal record is), a ClinicalTrials.gov search returning no Cartalax registration, and roughly a dozen vendor/aggregator pages. The convergent finding is no controlled human trial, preclinical-only biology, mild anecdotal safety, and very sparse community signal. Vendor copy is internally contradictory (one source miscalls it a 'dipeptide,' several conflate it with the AEDG tetrapeptide), which lowers source credibility.

Half-life and storage

Half-life: Not established in humans. Short peptides of this size are expected to be cleared within minutes by peptidases; online figures range from ~30 minutes to ~2-4 hours and are estimates, not measured human pharmacokinetics.

Once mixed: Supplied as a lyophilized powder; reported handling is reconstitution with bacteriostatic water, store lyophilized cold (2-8 C, or frozen -20 C for long-term), keep reconstituted product refrigerated at 2-8 C, avoid freeze-thaw cycles, and use within roughly 28 days. As with all peptides, heat, light, and repeated freeze-thaw degrade it; sterile technique matters because it is injected.

What people report

Volume of reports: faint. Little real-world record, or mostly noise.

Very low. Beyond vendor and SEO/affiliate articles, substantive first-hand community discussion is scarce, essentially a single notable forum thread plus scattered mentions; it is far less discussed than BPC-157 or TB-500.

Mixed and vague. The handful of positive anecdotes describe subtle 'joints feel smoother' impressions over weeks; reports are inconsistent, often hedged, and many community threads pivot to recommending other peptides instead.

Low. The information ecosystem is dominated by sellers and affiliate sites with internally contradictory facts (dipeptide vs tripeptide, AED vs AEDG), which means most 'signal' is marketing rather than independent user evidence; genuine unaffiliated testimony is thin.

• Anecdote, not proof: a small number of users report joints feeling smoother or less stiff after finishing a vial over several weeks, typically describing the effect as subtle rather than dramatic.
• Sentiment is lukewarm and uncertain; many discussions conclude that better-studied options like BPC-157 (or 'KLOW'-type blends) are a more sensible choice for joint and tissue repair.
• Tolerability is generally described as easy, with little beyond occasional injection-site irritation reported, consistent with the low-toxicity expectation for a tiny peptide.
• A recurring theme is difficulty separating real effect from placebo and from co-administered peptides, lifestyle, or training changes, so even satisfied users tend to hedge their attribution.

Reports are anecdote, not proof.

Can you tell if it is working?

First documented human use: No controlled human trial has ever been completed or registered. The molecule was synthesized by the St. Petersburg Institute of Bioregulation and Gerontology around 1999; vendor pages reference Russian "clinical" and "multi-center" use circa 2010-2015, but no protocol, patient count, endpoint, or peer-reviewed human result is published, and there is no ClinicalTrials.gov registration and no FDA/EMA evaluation. The most honest statement is that documented human use exists only as unreplicated Russian observational reports and gray-market self-experimentation.

1. ~1999AED (Ala-Glu-Asp) tripeptide synthesized by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology as a cartilage-targeted 'bioregulator.'
2. 2000sCell-culture and rodent studies from Russian laboratories report matrix-gene modulation, altered senescence markers, and cartilage effects (preclinical only).
3. ~2010-2015Vendor histories reference Russian 'clinical' and 'multi-center' use, but no protocol, patient numbers, endpoints, or peer-reviewed human results are published or registered.
4. 2020s-2026Sold internationally as a 'research peptide' / gray-market supplement; a Wikipedia entry appears, while community discussion remains sparse and frequently redirects to BPC-157 or other options.

• Wikipedia: Cartalax(Confirms AED tripeptide identity (C12H19N3O8), Russian origin, 'anti-aging effects in vitro and in animal models,' only limited human studies, and 'no legal status / missing ATC code.')
• ClinicalTrials.gov search: Cartalax(No registered human trials for Cartalax, corroborating the absent controlled-human-evidence finding.)
• PubMed search: cartalax (6 records, all preclinical)(Six indexed records, all preclinical (cell-culture/animal); illustrates how thin the AED-specific human record is.)
• PubMed: Khavinson peptide gene expression(Background for the assumed epigenetic/gene-expression mechanism of short Khavinson peptides, demonstrated mainly in vitro.)
• PubMed: Khavinson peptide bioregulator safety(Context for safety claims; no controlled human adverse-event dataset specific to Cartalax is indexed.)